Medicinal composition capable of preventing or treating inflammatory diseases

A composition and drug technology, applied in the direction of drug combination, allergic diseases, antipyretics, etc., can solve the problems of many adverse reactions and restrictions on widespread use

Inactive Publication Date: 2017-12-12
HAINAN SIMCERE PHARMA CO LTD +1
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are many adverse reactions in its clinic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition capable of preventing or treating inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1: The effect of hydroxychloroquine sulfate and iguratimod composition in treating arthritis in mice

[0026]Dosage group design: normal control group, model control group (normal saline), hydroxychloroquine sulfate (15mg / kg) group, iguratimod (1mg / kg) group, iguratimod (2mg / kg) group, hydroxychloroquine sulfate Chloroquine / iguratimod combined administration 2.8:1 group (5mg / kg hydroxychloroquine sulfate + 2mg / kg iguratimod), hydroxychloroquine sulfate / iguratimod combined administration 8.4:1 group (15mg / kg sulfuric acid Hydroxychloroquine + 2mg / kg iguratimod), hydroxychloroquine sulfate / iguratimod combined administration 16.7:1 group (15mg / kg hydroxychloroquine sulfate + 1mg / kg iguratimod), the ratio is molar Than calculate.

[0027] Construction of collagen mouse arthritis animal model: mice were used as test animals, 80 SPF grade DBA / 1 mice, male, 7-8 weeks old, weighing 18-22g, were randomly divided into 8 groups. Except for the normal group, the mou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal composition which comprises hydroxychloroquine and iguratimod, and further relates to applications of hydroxychloroquine and salts of hydroxychloroquine in preparing medicines capable of alleviating the toxic and side effects of iguratimod. The compound composition has the obvious effects of synergists and the obvious effect of reducing toxic and side effects.

Description

technical field [0001] The invention belongs to the field of medicines, in particular to a compound pharmaceutical composition of hydroxychloroquine and iguratimod. Background technique [0002] Inflammation contributes to the pathogenesis of inflammatory diseases or diseases associated with inflammation such as: (1) autoimmune diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE); (2) degenerative diseases such as osteoarthritis (OA); etc. Certain inflammatory conditions may be treated with anti-inflammatory agents including hydroxychloroquine or iguratimod. [0003] Hydroxychloroquine, whose chemical name is 2-[[4-[(7-chloro-4-quinolyl)amino]pentyl]ethylamino]-ethanol, belongs to antimalarial drugs like chloroquine, because it has the ability to inhibit antigen presentation, Inhibit synovial hyperplasia and other effects, has been used in the treatment of rheumatic diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren's s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4706A61K31/352A61P29/00A61P37/02
CPCA61K31/352A61K31/4706A61K2300/00A61P29/00A61P37/02
Inventor 冯洪刚许向阳刘彩连
Owner HAINAN SIMCERE PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap